Liver's immune secrets targeted in rare eye cancer study
NCT ID NCT07364474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the liver's immune system reacts to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. It involves 10 adults with uveal melanoma that has spread to the liver. The goal is to understand immune changes, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- Can a pill prevent eye cancer spread? new trial aims to find out
- New drug shows promise in shrinking eye cancer before surgery